Диссертация (1150004), страница 18
Текст из файла (страница 18)
И.Киселева, Л. М. Цыбалова, В. И. Покровского – М.: Изд-во МИА, – 2012. – 496с.90. Palese, P.; Compans, R. W. Inhibition of influenza virus replication in tissuecultureby2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminicacid(FANA):mechanism of action // J. Gen. Virol. – 1976. – Vol. 33. – P. 159–163.91. Klenk, H.
D.; Rott, R. The molecular biology of influenza virus pathogenicity //Adv. Virus Res. – 1988. – Vol. 34. – P. 247–281.92. Russell, R. J.; Haire, L. F.; Stevens, D. J.; Collins, P. J.; Lin, Y. P.; Blackburn, G.M.; Hay, A. J. The structure of H5N1 avian influenza neuraminidase suggests newopportunities for drug design// Nature. – 2006. – Vol. 44. – P. 45–49.93.
Amaro, R. E.; Minh, D. D. L.; Cheng, L. S.; Lindstrom Jr, W. M.; Olson, A. J.;Lin, J. H.; Li, W. W.; McCammon, J. A. Remarkable loop flexibility in avianinfluenza N1 and its implications for antiviral drug design // J. Am. Chem. Soc. –2007. – Vol. 129. – P. 7764–7765.94. Amaro, R. E.; Swift, R. V.; Votapka, L.; Li, W.
W.; Walker, R. C.; Bush, R. M.Mechanism of 150-cavity formation in influenza neuraminidase // Nat. Commun. –2011. – Vol. 2. – P. 388.95. García-Sosa, A. T.; Sild, S.; Maran, U. Design of multi-binding-site inhibitors,ligand efficiency, and consensus screening of avian influenza H5N1 wild-type115neuraminidase and of the oseltamivir-resistant H274Y variant // J. Chem.
Inf. Model.– 2008. – Vol. 48. – P. 2074–2080.96. Cheng, L. S.; Amaro, R. E.; Xu, D.; Li, W. W.; Arzberger, P. W.; McCammon, J.A. Ensemble-based virtual screening reveals potential novel antiviral compounds foravian influenza neuraminidase // J. Med. Chem.
– 2008. – Vol. 51. – P. 3878–3894.97. Yan, L.; Bingcheng, Z.; Renxiao, W. Rational design of Tamiflu derivativestargeting at the open conformation of neuraminidase subtype 1 // J. Mol. Graph. –2009. – Vol. 28. – № 3. – P. 203–219.98. Mitrasinovic, P.M. On the structure-based design of novel inhibitors of H5N1influenza A virus neuraminidase (NA) // Biophys. Chem. – 2009. – Vol. 140. – № 13. – P. 35–38.99.
Wen-Hsien, W.; Shi-Yun, W.; Keng-Chang, T.; Yih-Shyun E, C.; An-Suei, Y.;Jim-Min, F.; Chi-Huey, W. Analogs of zanamivir with modified C4-substituents asthe inhibitors against the group-1 neuraminidases of influenza viruses // Bioorg. Med.Chem. – 2010. – Vol. 18. – № 11. – P. 4074–4084.100. Rudrawar, S.; Dyason, J. C.; Rameix-Welti, M.-A.; Rose, F. J.; Kerry, P.
S.;Russell, R. J. M.; van der Werf, S.; von Itzstein, M. et al. Novel sialic acid derivativeslock open the 150-loop of an influenza A virus group-1 sialidase // Nat. Commun. –2010. – Vol. 1. – P. 113.101. Varghese, J. N.; McKimm-Breschkin, J. L.; Caldwell, J. B.; Kortt, A. A.;Colman, P. M. The structure of the complex between influenza virus neuraminidaseand sialic acid, the viral receptor // Proteins. – 1992.
– Vol. 14. – № 3. – P. 327–332.102. White, C. L.; Janakiraman, M. N.; Laver, W. G.; Philippon, C.; Vasella, A.; Air,G. M.; Luo, M. A sialic acid-derived phosphonate analog inhibits different strains ofinfluenza virus neuraminidase with different efficiencies // J. Mol. Biol. – 1995. –Vol. 245. – № 5. – P. 623–634.103. von Itzstein, M.; Wu, W. Y.; Kok, G.
B.; Pegg, M. S.; Dyason, J. C.; Jin, B.;Van Phan, T.; Oliver, S. W. et al. Rational design of potent sialidase-based inhibitorsof influenza virus replication // Nature. – 1993. – Vol. 363. – № 6428. – P. 418–423.116104. Kim, C. U.; Lew, W.; Williams, M. A.; Liu, H.; Zhang, L.; Swaminathan, S.;Bischofberger, N.; Stevens, R. C. et al. Influenza neuraminidase inhibitors possessinga novel hydrophobic interaction in the enzyme active site: design, synthesis, andstructural analysis of carbocyclic sialic acid analogues with potent anti-influenzaactivity // J.
Am. Chem. Soc. – 1997. – Vol. 119. – № 4. – P. 681–690.105. Kati, W. M.; Montgomery, D.; Carrick, R.; Gubareva, L.; Maring, C.; McDaniel,K.; Steffy, K.; Kohlbrenner, W. et al. In Vitro Characterization of A-315675, aHighly Potent Inhibitor of A and B Strain Influenza Virus Neuraminidases andInfluenza Virus Replication // Antimicrob. Agents Chemother. – 2002. – Vol. 46. – P.1014–1021.106.
Babu, Y. S.; Chand, P.; Bantia, S.; Kotian, P.; Dehghani, A.; El-Kattan, Y.; Lin,T. H.; Montgomery, J. A. et al. BCX-1812 (RWJ-270201): discovery of a novel,highly potent, orally active, and selective influenza neuraminidase inhibitor throughstructure-based drug design // J. Med. Chem. – 2000.
– Vol. 43. – № 19. – P. 3482–3486.107. Yamashita, M.; Tomozawa, T.; Kakuta, M.; Tokumitsu, A.; Nasu, H.; Kubo, S."CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows longacting anti-influenza virus activity // Antimicrobial Agents and Chemotherapy.
–2009. – Vol. 53. – № 1. – P. 186–192.108. Meeprasert, A.; Khuntawee, W.; Kamlungsua, K.; Nunthaboot, N.;Rungrotmongkol, T.; Hannongbua, S. Binding pattern of the long actingneuraminidase inhibitor laninamivir towards influenza A subtypes H5N1 andpandemic H1N1 // Journal of molecular graphics & modelling. – 2012. – Vol. 38. –P.148-154.109. Mishin, V. P.; Hayden, F. G.; Gubareva, L. V. Susceptibilities of antiviralresistant influenza viruses to novel neuraminidase inhibitors // Antimicrobial Agentsand Chemotherapy. – 2005. – Vol. 49.
– № 11. – P. 4515–4520.110. Yen, H.-L.; Herlocher, L. M.; Hoffmann, E.; Matrosovich, M. N.; Monto, A. S.;Webster, R. G.; Govorkova, E. A. et al. Neuraminidase inhibitor-resistant influenza117viruses may differ substantially in fitness and transmissibility // Antimicrobial Agentsand Chemotherapy. – 2005. – Vol. 49. – № 10.
– P. 4075–4084.111. Sharma, M.; Yi, M.; Dong, H.; Qin, H.; Peterson, E.; Busath, D. D.; Zhou, H.X.; Cross, T. A. Insight into the mechanism of the influenza A proton channel from astructure in a lipid bilayer // Science. – 2010. – Vol. 330. – № 6003. – P. 509–512.112. Rossman, J. S.; Lamb, R. A. Influenza virus assembly and budding // Virology.– 2011. – Vol. 411. – № 2. – P. 229–236.113. Chen, B. J.; Leser, G. P.; Jackson, D.; Lamb, R. A.
et al. The influenza virus M2protein cytoplasmic tail interacts with the M1 protein and influences virus assemblyat the site of virus budding // J. Virol. – 2008. – Vol. 82. – № 20. – P. 10059–10070.114. Hu, J.; Fu, R.; Nishimura, K.; Zhang, L.; Zhou, H.-X.; Busath, D. D.;Vijayvergiya, V.; Cross, T. A. Histidines, heart of the hydrogen ion channel frominfluenza A virus: toward an understanding of conductance and proton selectivity //Proc. Natl Acad. Sci.
U. S. A. – 2006. – Vol. 103. – № 18. – P. 6865–6870.115. Venkataraman, P.; Lamb, R. A.; Pinto, L. H. Chemical rescue of histidineselectivity filter mutants of the M2 ion channel of influenza A virus // J. Biol. Chem.– 2005. – Vol. 280. – № 22. – P. 21463–21472.116. Tang, Y.; Zaitseva, F.; Lamb, R. A.; Pinto, L. H. The gate of the influenza virusM2 proton channel is formed by a single tryptophan residue // J. Biol. Chem.
– 2002.– Vol. 277. – № 42. – P. 39880–39886.117. Du, J.; Cross, T. A.; Zhou, H.-X. Recent progress in structure-based antiinfluenza drug design // Drug discovery today. – 2012. – Vol. 17. – № 19-20. – P.1111–1120.118. Jackson, G. G.; Mudloon, R. L.; Akers, L. W. Serological evidence forpreventionofinfluenzainfectionsinvolunteersbyanti-influenzadrugadamantanamine hydrochloride // Antimiocrob. Agents Chemother. – 1963. – Vol.161. – P.
703–707.119. Stouffer, A. L.; Acharya, R.; Salom, D.; Levine, A. S.; Di Costanzo, L.; Soto, C.S.; Tereshko, V.; DeGrado, W. F. et al. Structural basis for the function and inhibition118of an influenza virus proton channel // Nature. – 2008. – Vol. 451. – № 7178. – P.596–599.120. Hu, J.; Asbury, T.; Achuthan, S.; Li, C.; Bertram, R.; Quine, J. R.; Fu, R.; Cross,T. A. Backbone structure of the amantadine-blocked trans- membrane domain M2proton channel from influenza A virus // Biophys.
J. – 2007. – Vol. 92. – № 12. – P.4335–4343.121. Yi, M.; Cross, T. A.; Zhou, H.-X. A secondary gate as a mechanism forinhibition of the M2 proton channel by amantadine // J. Phys. Chem. B. – 2008. –Vol. 112. – № 27. – P. 7977–7979.122. Cady, S. D.; Schmidt-Rohr, K.; Wang, J.; Soto, C. S.; Degrado, W.
F.; Hong, M.Structure of the amantadine binding site of influenza M2 proton channels in lipidbilayers // Nature. – 2010. – Vol. 463. – № 7281. – P. 689–692.123. Cross, T. A.; Dong, H.; Sharma, M.; Busath, D. D.; Zhou, H.-X. M2 proteinfrom influenza A: from multiple structures to biophysical and functional insights //Curr. Opin. Virol. – 2012. – Vol. 2.
– № 2. – P. 128–133.124. Hu, W.; Zeng, S.; Li, C.; Jie, Y.; Li, Z.; Chen, L. Identification of hits as Matrix2 protein inhibitors through the focused screening of a small primary amine library //J. Med. Chem. – 2010. – Vol. 53. – № 9. – P. 3831–3834.125. Zhao, X.; Li, C.; Zeng, S.; Hu, W. Discovery of highly potent agents againstinfluenza A virus // Eur. J. Med. Chem. – 2011. – Vol. 46. – № 1. – P. 52–57.126.
Wang, J.; Ma, C.; DeGrado, W. F. et al. Exploring the requirements for thehydrophobic scaffold and polar amine in inhibitors of M2 from influenza A virus //ACS Med. Chem. Lett. – 2011. – Vol. 2. – № 4. – P. 307–312.127. Duque, M. D.; Ma, C.; Torres, E.; Wang, J.; Naesens, L.; Juárez-Jiménez, J.;Camps, P.; Vázquez, S. et al. Exploring the size limit of templates for inhibitors ofthe M2 ion channel of influenza A virus // J.
Med. Chem. – 2011. – Vol. 54. – № 8. –P. 2646–2657.128. Kurtz, S.; Luo, G.; Hahnenberger, K. M.; Brooks, C.; Gecha, O.; Ingalls, K.;Numata, K.; Krystal, M. Growth impairment resulting from expression of influenzavirus M2 protein in Saccharomyces cerevisiae: identification of a novel inhibitor of119influenza virus // Antimicrob.
Agents Chemother. – 1995. – Vol. 39. – № 10. – P.2204–2209.129. Wang, J.; Cady, S. D.; Balannik, V.; Pinto, L. H.; DeGrado, W. F.; Hong, M.Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of theM2 proton channel from influenza A virus // J. Am. Chem. Soc. – 2009. – Vol. 131. –№ 23. – P. 8066–8076.130.
Balannik, V.; Wang, J.; Ohigashi, Y.; Jing, X.; Magavern, E.; Lamb, R. A.;Degrado, W. F.; Pinto, L. H.; Design and pharmacological characterization ofinhibitors of amantadine-resistant mutants of the M2 ion channel of influenza A virus// Biochemistry. – 2009. – Vol. 48. – № 50. – P. 11872–11882.131. Wang, J.; Ma, C.; Fiorin, G.; Carnevale, V.; Wang, T.; Hu, F.; Lamb, R.
A.;DeGrado, W. F. et al. Molecular dynamics simulation directed rational design ofinhibitors targeting drug-resistant mutants of influenza A virus M2 // J. Am. Chem.Soc. – 2011. – Vol. 133. – № 32. – P. 12834–12841.132. Wang, J.; Ma, C.; Wu, Y.; Lamb, R. A.; Pinto, L. H.; DeGrado, W. F. Exploringorganosilane amines as potent inhibitors and structural probes of influenza A virusM2 proton channel // J. Am. Chem.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
